Allarity Therapeutics, Inc. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Allarity Therapeutics, Inc. (ALLR) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$3.08 million for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-27.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2023-03-13
- Allarity Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2022-03-31 was -$3.08M.
- Allarity Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2021-03-31 was -$3.08M.
- Allarity Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2020-12-31 was $0.00.
- Allarity Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2021 was -$9.00K, a 160.00% decline from fiscal 2020.
- Allarity Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2020 was $15.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2022-03-31 | -$3.08M 10-Q · filed 2022-05-27 | |||
| 2021-12-31 | -$9.00K 10-K · filed 2023-03-13 | |||
| 2021-03-31 | -$3.08M 10-Q · filed 2022-05-27 | -$3.08M derived: sum of 2 quarters · filed 2022-05-27 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q/A 9 month · filed 2022-05-17 | $15.00K 10-K · filed 2022-05-17 | ||
| 2020-09-30 | $15.00K 10-Q/A · filed 2022-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B |